| 臺大學術典藏 |
2021-09-04T06:11:30Z |
Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection
|
Cheng H.-R.; JIA-HORNG KAO; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Su T.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:29Z |
New insights into the evolutionary rate of hepatitis B virus at different biological scales
|
Lin Y.-Y.; Liu C.; Chien W.-H.; Wu L.-L.; Tao Y.; Wu D.; Lu X.; Hsieh C.-H.; Chen P.-J.; Wang H.-Y.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:29Z |
Treating Immune-tolerant Hepatitis B
|
Tseng, T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:29Z |
Improving clinical outcomes of chronic hepatitis B virus infection
|
Su T.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:28Z |
Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection
|
Song L.-W.; Liu P.-G.; Liu C.-J.; Zhang T.-Y.; Cheng X.-D.; Wu H.-L.; Yang H.-C.; Hao X.-K.; Yuan Q.; Zhang J.; JIA-HORNG KAO; Chen D.-S.; Chen P.-J.; Xia N.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:28Z |
Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection
|
Hsu C.-S.; Liu W.-L.; Chao Y.-C.; Lin H.H.; Tseng T.-C.; Wang C.-C.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:28Z |
HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
|
Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:27Z |
Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping
|
Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:27Z |
Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy
|
Liang C.-C.; Liu C.-H.; Chung C.-S.; Lin C.-K.; Su T.-H.; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:27Z |
Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection
|
Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:26Z |
Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system
|
Liu J.; Tseng T.-C.; Yang H.-I.; Lee M.-H.; Batrla-Utermann R.; Jen C.-L.; Lu S.-N.; Wang L.-Y.; You S.-L.; Chen P.-J.; Chen C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:26Z |
Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma
|
Hsu C.-S.; Chao Y.-C.; Lin H.H.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:25Z |
Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:25Z |
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
|
Buti M.; Flisiak R.; JIA-HORNG KAO; Chuang W.-L.; Streinu-Cercel A.; Tabak F.; Calistru P.; Goeser T.; Rasenack J.; Horban A.; Davis G.L.; Alberti A.; Mazzella G.; Pol S.; Orsenigo R.; Brass C. |
| 臺大學術典藏 |
2021-09-04T06:11:25Z |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
|
Su T.-H.; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:24Z |
Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure
|
Zeisel M.B.; Lucifora J.; Mason W.S.; Sureau C.; Beck J.; Levrero M.; Kann M.; Knolle P.A.; Benkirane M.; Durantel D.; Michel M.-L.; Autran B.; Cosset F.-L.; Strick-Marchand H.; Tr?po C.; JIA-HORNG KAO; Carrat F.; Lacombe K.; Schinazi R.F.; Barr?-Sinoussi F.; Delfraissy J.-F.; Zoulim F. |
| 臺大學術典藏 |
2021-09-04T06:11:24Z |
A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan
|
Bennett H.; Waser N.; Johnston K.; JIA-HORNG KAO; Lim Y.-S.; Duan Z.-P.; Lee Y.-J.; Wei L.; Chen C.-J.; Sievert W.; Yuan Y.; Li H. |
| 臺大學術典藏 |
2021-09-04T06:11:23Z |
Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: A nation-wide cohort study
|
Huang Y.-W.; Wang T.-C.; Yang S.-S.; Lin S.-Y.; Fu S.-C.; Hu J.-T.; Liu C.-J.; JIA-HORNG KAO; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:23Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:23Z |
Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers
|
Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; Su T.-H.; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:22Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; JIA-HORNG KAO; Yu M.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:22Z |
Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma
|
Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:21Z |
Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study
|
Liu C.-H.; Sheng W.-H.; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; Su T.-H.; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:21Z |
Looking into the crystal ball: biomarkers for outcomes of HBV infection
|
Yang H.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:21Z |
Hepatitis B virus: New therapeutic perspectives
|
Lin C.-L.; Yang H.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:21Z |
Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:20Z |
Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model
|
Li Y.-T.; Liu C.-J.; Su T.-H.; Cheng H.-R.; Jeng Y.-M.; Lin H.-L.; Wang C.-C.; JIA-HORNG KAO; Chen P.-J.; Chen D.-S.; Wu H.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:20Z |
Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis
|
Yang H.-I.; Tseng T.-C.; Liu J.; Lee M.-H.; Liu C.-J.; Su T.-H.; Batrla-Utermann R.; Chan H.L.Y.; JIA-HORNG KAO; Chen C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:19Z |
HIV/HCV coinfection in Taiwan
|
Hsu C.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:19Z |
Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: Fact or fiction?
|
Liu C.-H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:19Z |
New perspectives of biomarkers for the management of chronic hepatitis B
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:19Z |
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
|
Sarin S.K.; Kumar M.; Lau G.K.; Abbas Z.; Chan H.L.Y.; Chen C.J.; Chen D.S.; Chen H.L.; Chen P.J.; Chien R.N.; Dokmeci A.K.; Gane E.; Hou J.L.; Jafri W.; Jia J.; Kim J.H.; Lai C.L.; Lee H.C.; Lim S.G.; Liu C.J.; Locarnini S.; Al Mahtab M.; Mohamed R.; Omata M.; Park J.; Piratvisuth T.; Sharma B.C.; Sollano J.; Wang F.S.; Wei L.; Yuen M.F.; Zheng S.S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan
|
Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; Su T.-H.; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study
|
Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:18Z |
Hepatitis C virus infection in Taiwan: Past, present, and future
|
JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Faldaprevir, pegylated interferon, and ribavirin for treatment-na?ve HCV genotype-1: Pooled analysis of two phase 3 trials
|
Jensen D.M.; Asselah T.; Dieterich D.; Foster G.R.; Sulkowski M.S.; Zeuzem S.; Mantry P.; Yoshida E.M.; Moreno C.; Ouzan D.; Wright M.; Morano L.E.; Buynak R.; Bourli?re M.; Hassanein T.; Nishiguchi S.; JIA-HORNG KAO; Omata M.; Paik S.W.; Wong D.K.; Tam E.; Kaita K.; Victor Feinman S.; Stern J.O.; Scherer J.; Quinson A.-M.; Voss F.; Gallivan J.-P.; B?cher W.O.; Ferenci P. |
| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection
|
Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; Su T.-H.; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:17Z |
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
|
Yang S.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:16Z |
How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?
|
Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:16Z |
Perspectives on dual hepatitis B and C infection in Taiwan
|
Liu C.-J.; Chen P.-J.; Chen D.-S.; Tseng T.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
|
JIA-HORNG KAO; Jensen D.M.; Manns M.P.; Jacobson I.; Kumada H.; Toyota J.; Heo J.; Yoffe B.; Sievert W.; Bessone F.; Peng C.-Y.; Roberts S.K.; Lee Y.-J.; Bhore R.; Mendez P.; Hughes E.; Noviello S. |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Management of hepatitis C patients with decompensated liver disease
|
Hsu C.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:15Z |
Efficacy of entecavir therapy for hepatitis B e-antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues
|
Tseng K.-C.; Tseng C.-W.; Hsieh T.-Y.; Peng C.-Y.; Lin C.-L.; Su T.-H.; Tseng T.-C.; Lin H.H.; Wang C.-C.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
|
JIA-HORNG KAO; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L. |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus
|
Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:14Z |
Review article: novel therapies for hepatitis B virus cure – advances and perspectives
|
Lin C.-L.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:13Z |
Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg
|
Wang C.-C.; Tseng K.-C.; Hsieh T.-Y.; Tseng T.-C.; Lin H.H.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:13Z |
Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy
|
Hsu C.-S.; Hsu S.-J.; Liu W.-L.; Chen D.-S.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-09-04T06:11:13Z |
Liver gene expression profiles correlate with virus infection and response to interferon therapy in chronic hepatitis B patients
|
Wu H.-L.; Hsiao T.-H.; Chen P.-J.; Wong S.-H.; JIA-HORNG KAO; Chen D.-S.; Lu J.-Y.; Lu T.-P.; Chen Y.; Chuang E.Y.; Tu H.-C.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T06:11:12Z |
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing
|
Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO; Yokosuka O.; Lau G.K.K.; Sarin S.K. |
